Concerto Biosciences

Concerto Biosciences combines automated experimentation and AI to map microbial interactions. Founded in 2020, it raised a $23 million Series A, advanced an atopic-dermatitis candidate into clinical testing and signed a 2026 development agreement with Sacco System.

Facts

Segment: Lab Automation
Country: United States
Founded: 2020
Website: https://www.concertobio.com

Funding

2022-11-02 - Series A - $23M - Concerto Biosciences raises $23 million Series A - Concerto Biosciences raised $23 million to advance its microbial discovery platform, product pipeline and first-in-human development work. - source: concertobio.com

View funding

Investors

Horizons Ventures - Participant - VC - 1 funding event - first seen 2022-11-02
M Ventures - Participant - VC - 1 funding event - first seen 2022-11-02
Safar Partners - Participant - VC - 1 funding event - first seen 2022-11-02

View investors

Market context

Comparable profiles and adjacent companies connected by shared workflow, capability, or stack position.

Opentrons - comparable profile - peer: Lab Automation Platform Builder
Overture Life - comparable profile - peer: Lab Automation Platform Builder
Tenomix - comparable profile - peer: Lab Automation Platform Builder

View market context

Timeline

2026-01-29 - Partnership - Concerto and Sacco System sign development and commercialization agreement - The programme combines Concerto’s kChip and kAI discovery platform with Sacco System’s development and production capabilities. Work targets next-generation microbial ingredients. The agreement spans discovery, development and commercialization. - source: concertobio.com

View timeline

Relations

Sacco System - Development And Commercialization Partner - Concerto and Sacco System signed a microbial ingredient development and commercialization agreement.

View relations